A moving tribute at #PCFretreat26: @JoshLangMD honored Dr. Felix Feng with lessons in knowing your why, moving faster together, mentoring, and putting people first. Felix's words👉: "There is always a patient behind each of those studies”, like him. @PCF_Science @urotoday

Dr. Himisha Beltran of @DanaFarber Cancer Institute takes the stage at #PCFRetreat26 to spotlight the power of academic-industry partnerships to drive innovation, accelerate discovery and bring new treatment approaches to patients faster. #ScientificRetreat

Congrats to Dr. Mary-Ellen Taplin @DanaFarber_GU 👉 “@PCF_News Women in Science Lifetime Achievement Award at #PCFRetreat26! 🎉 a career spent following the questions & putting patients first. A well-deserved standing ovation. 👏 @PCF_Science @urotoday @DrChoueiri @DanaFarber

In the @PCF_Science #PCFretreat26 , enjoyed the brilliant talk by, @mishabeltran @DanaFarber_GU 👉Mechanism of resistance to PSMA directed RLT Rx, tips for young investigators, and the value of team science (quote from Dr. Felix Feng) @PCF_Science @urotoday @DanaFarber

Thrilled to share I've received the NIH/NCI K99/R00 Award!

Deeply grateful to my mentor @mishabeltran for her immense support, my advisory committee and referees, and to @PCF_Science and DoD for early funding that made this possible.

A message to @NazliDizman:

Today you will graduate from your #oncology fellowship at @UTMDAnderson. The picture below is from the 2016 @myESMO meeting in Copenhagen just after you started with my group at @cityofhope. You were my first postdoctoral fellow, and honestly, I ck I was doing when it came to mentoring you. The fortunate thing is you were a self starter & made my job incredibly easy, paving a clear path not just for yourself but for the trainees that came after. It's been a joy to see all that you have accomplished - publishing in @NatureMedicine, @TheLancetOncol, @JCO_ASCO & other top tier journals, getting amazing young investigator grants from @ASCO, @KidneyCancer & more & racking up more @ConquerCancerFd Merit Awards than any other trainee in recent memory (maybe tied with @crisbergerot?). Along the way, you've kept a humility & kindness about you that is unmatched, always willing to lend a hand to your junior colleagues. Your road has not been an easy one, coming from tumultuous times abroad to @cityofhope, then to @YaleIMed and then to @UTMDAnderson, but this arduous road has equipped you well for your first faculty position at @DanaFarber. I am so proud to see you join a group of oncology luminaries at @Harvard (@DrChoueiri, @KimmieNgMD, @stolaney1, @mishabeltran & so many others!!) - I am confident your stellar trajectory will continue further with their support. Enjoy Boston and know that you will always have support & good vibes coming from the west coast.

All the best,

#WorkDad

⭐ Neuroendocrine prostate cancer (NEPC) — where are we now?
@OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin

🎤 Presented by Himisha Beltran
🔥 Excellent talk — a complex field but full of opportunities
🔹 Key insights 👇

🔵 Biology matters
➡️ NEPC is highly o vs treatment-emergent → different trajectories
🔵 Current standard
➡️ Treat like SCLC
➡️ Platinum-based chemotherapy remains backbone
🔵 DLL3 as a target 🎯
➡️ Highly specific to NE tumors
➡️ Tarlatamab shows promising activity (ORR ~40–100% depending on expression)
⚠️ But: marked intra/inter-patient heterogeneity

🔵 Beyond DLL3
➡️ Emerging strategies: ADCs, BiTEs, IO combos, epigenetic targets
➡️ Rational combinations under active investigation
🔵 Clinical nuances
➡️ Consider platinum rechallenge in selected patients
➡️ Need better definitions & timing (≥3–6 months?)
🔹 Take-home
NEPC ≠ one disease
➡️ Precision selection is critical to move beyond chemotherapy
@tompowles1 @brian_rini @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb
#ProstateCancer #NEPC #Oncology #PrecisionMedicine

LBA1/Plenary #ASCO26: PROTEUS trial
Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC

Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is ent question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage !

@DanaFarber @DanaFarber_GU @ASCO @OncoAlert

After 28 years of visionary leadership, @soulehoward1 is retiring from PCF. His work has transformed treatments & impacted countless patients.

We’re excited to welcome VP of Global Research & Innovation @AndreaMiyahira as we continue driving progress in prostate cancer research.

PROX1 explored as a driver of neuroendocrine #ProstateCancer progression. @Bajji @DanaFarber joins @AndreaMiyahira @PCFnews in discussing #PROX1 as an epigenetically derepressed driver in neuroendocrine prostate cancer. #WatchNow on UroToday > bit.ly/47kzVEk

Excited to share our new paper @NatureComms in collaboration with @RickmanLab, led by #RichaSingh @WeillCornell and @Bajji @DanaFarber #BeltranLab

The Feng Symposium in Prostate Cancer is a reminder of all of us about the exceptional legacy of Dr Felix Feng in mentorship and prostate cancer research impact

@ASCOPres @mishabeltran @JoshLangMD @DrRanaMcKay @MaryFengMD

Just out today in @jclinicalinvest 🚀
mHSPC is not one disease, but a kaleidoscope of biological states. We highlight what we know — and the key gaps that remain — on the road to precision medicine✨
Led by my mentor @mishabeltran 🙌
#ProstateCancer #mHSPC #PrecisionOncology

Great lightening talks by Beltran Lab members Balaji and Jake presenting their latest work! #AACRProstate26 @DanaFarber_GU

No small feat to be FULL PROFESSOR of MEDICINE @harvardmed ! Congrats Misha and Joaquim on this extremely high distinction!

We are all @DanaFarber_GU and @DanaFarber proud!

Congratulations Dr Alice Bernard-Tessier ⁦@alicebernardt⁩ for receiving a PCF YIA! #proudmentor #BeltranLab ⁦@DanaFarber_GU⁩ @GustaveRoussy⁩ ⁦@PCF_Science⁩ ⁦@DrChoueiri⁩

En route to #PCFRetreat25--my first without Felix. Rewatched this incredible session from last yr: pcf.org/2024-scientifi…
What a tribute by Amina and Misha, and Felix's words about the @PCFnews community are so meaningful.

"Behind every study, there's always a patient like me"

Elegant talk from @alicebernardt at #ESMO25 highlighting novel AR directed therapies. PROTACS, N-terminal domain inh, etc all covered. We met via @AlbigesL @GustaveRoussy on the DFF332 trial for #kidneycancer - excited to hear that she is doing a fellowship at @DanaFarber with an.

🆙#ESMO25🇩🇪
🔥#LCSM Mini Oral, non-mets, SCLC
☑️Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers
☑️ORR 44%, DCR 66%
🎙️ Dr. Himisha Beltran
@OncoAlert @myESMO @Larvol

Thank you prostate scientist-extraordinaire @JoshLangMD for coming to our @DanaFarber Grand Rounds “Sweeney Lecture @Si. Elegant work in CTC at the crossroads of translational research and bioengineering! cc: @DanaFarber_GU @mishabeltran